Eli Lilly faces employee complaints, FDA troubles at factory making COVID-19 drug: report

Quality control problems have already plagued one COVID-19 vaccine manufacturer in Baltimore, Maryland. Now, it appears they’re threatening to trip up a major pandemic therapeutic supplier as well. Eli Lilly employees have accused an executive at the drugmaker’s Branchburg, New Jersey, manufacturing site of altering FDA-required documents in an effort to downplay serious quality control problems, Reuters reported on Wednesday, citing internal complaint documents and a source familiar with the matter. The complaint, dated April 8, said the executive tasked with quality controls rewrote findings from Lilly’s technical experts at the facility, which produces doses of the company’s COVID-19 antibody treatment bamlanivimab, in order to make them look more favorable, according to the report.